ContributorsPublishersAdvertisers

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

onclive.com
 2022-01-22

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors. David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The...

www.onclive.com

Comments / 0

Comments / 0